Myriad Genetics is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. At the end of fiscal year 2015, Myriad had annual revenue of approximately $723.1 million and 2,038 employees,
Myriad is the global leader and pioneer in the molecular diagnostics field with twelve innovative diagnostic products. Through our proprietary technologies, we believe we are positioned to identify important disease genes, the proteins they produce, and the biological pathways in which they are involved to better understand the genetic basis of human disease and the role that genes and their related proteins may play in the disease process.
Myriad Genetics was founded in 1992 and is headquartered in Salt Lake City, US
Myriad Genetics Office Locations
Myriad Genetics has offices in Salt Lake City, Austin, Zürich and South San Francisco
Salt Lake City, US (HQ)
320 Wakara Way
South San Francisco, US
341 Oyster Point Blvd
Zürich, CH
95 Leutschenbachstrasse
Austin, US
3300 Duval Rd
Myriad Genetics Data and Metrics
Myriad Genetics Financial Metrics
Myriad Genetics's revenue was reported to be $196.9 m in Q3, 2017
USD
Revenue (Q3, 2017) | 196.9 m |
Net income (Q3, 2017) | 4.2 m |
EBIT (Q3, 2017) | 12.9 m |
Market capitalization (21-Jul-2017) | 1.7 b |
Cash (31-Mar-2017) | 123.8 m |
Myriad Genetics's current market capitalization is $1.7 b.
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Revenue | 778.2 m | 723.1 m | 753.8 m |
Revenue growth, % | (7%) | 4% | |
Gross profit | 682.1 m | 590.3 m | |
Gross profit Margin, % | 88% | 82% | |
Operating expense total | 407.6 m | 456.1 m | 454.2 m |
EBIT | 274.4 m | 134.2 m | 166.8 m |
EBIT margin, % | 35% | 19% | 22% |
Interest income | 5.4 m | 400 k | 900 k |
Pre tax profit | 277.9 m | 134.9 m | 168.9 m |
Income tax expense | 101.6 m | 54.7 m | 43.6 m |
Net Income | 176.2 m | 80.2 m | 125.3 m |
| USD | Q1, 2014 | Q2, 2014 | Q3, 2015 | Q1, 2015 | Q2, 2015 | Q3, 2016 | Q1, 2016 | Q2, 2016 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 168.8 m | 184.4 m | 180 m | 183.5 m | 193.3 m | 190.5 m | 177.5 m | 196.5 m | 196.9 m |
EBIT | 25.9 m | 36.3 m | 35.7 m | 43.3 m | 45.2 m | 42.6 m | 6.2 m | 13.2 m | 12.9 m |
EBIT margin, % | 15% | 20% | 20% | 24% | 23% | 22% | 3% | 7% | 7% |
Interest income | 55 k | 85 k | 124 k | 100 k | 100 k | 300 k | 300 k | 300 k | 300 k |
Pre tax profit | 25.9 m | 37.9 m | 35.6 m | 43.5 m | 45 m | 43.1 m | 4 m | 12.1 m | 8 m |
Net Income | 16 m | 24 m | 21.5 m | 26.6 m | 30.3 m | 32.6 m | (1.2 m) | 5.9 m | 4.2 m |
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Cash | 64.8 m | 64.1 m | 68.5 m |
Accounts Receivable | 3.8 m | 1.9 m | 3.3 m |
Inventories | 23.9 m | 25.1 m | 38.3 m |
Current Assets | 322.4 m | 283.6 m | 314.5 m |
PP&E | 67.2 m | 58.3 m | |
Goodwill | 169.2 m | 177.2 m | 195.3 m |
Total Assets | 823.8 m | 766.2 m | 880.5 m |
Accounts Payable | 23.1 m | 21.1 m | 21.1 m |
Current Liabilities | 80.6 m | 68.7 m | 72.3 m |
Total Liabilities | 132.4 m | ||
Additional Paid-in Capital | 717.8 m | 745.4 m | 830.1 m |
Retained Earnings | 2 m | (77 m) | (73.2 m) |
Total Equity | 719 m | 662.1 m | 748.1 m |
Financial Leverage | 1.1 x | 1.2 x | 1.2 x |
| USD | Q1, 2014 | Q2, 2014 | Q3, 2015 | Q1, 2015 | Q2, 2015 | Q3, 2016 | Q1, 2016 | Q2, 2016 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 69.8 m | 59.7 m | 55.2 m | 87.4 m | 134.7 m | 120.5 m | 86.9 m | 108.1 m | 123.8 m |
Accounts Receivable | 11.2 m | 5.3 m | 3 m | 1.6 m | 5.1 m | 2.9 m | 4.6 m | 3.9 m | 4.4 m |
Inventories | 24.8 m | 20.2 m | 29.4 m | 34.3 m | 29.1 m | 25.3 m | 53.9 m | 51.3 m | 47.4 m |
Current Assets | 335.4 m | 320.1 m | 282.4 m | 307.3 m | 375.5 m | 372.4 m | 322.9 m | 341.6 m | 348.3 m |
PP&E | 64.9 m | 61.7 m | 60 m | 56.8 m | 54.7 m | 53 m | |||
Goodwill | 169.2 m | 169.2 m | 185.2 m | 177.3 m | 177 m | 177.9 m | 312.8 m | 315.4 m | 315 m |
Total Assets | 809 m | 781.9 m | 779 m | 787 m | 871.7 m | 868.2 m | 1.3 b | 1.3 b | 1.3 b |
Accounts Payable | 25.7 m | 16.8 m | 18 m | 15.8 m | 16.5 m | 13.8 m | 19.9 m | 22.9 m | 26.8 m |
Current Liabilities | 67.7 m | 59.8 m | 67.2 m | 59 m | 65.9 m | 66.1 m | 274.9 m | 82.8 m | 221.7 m |
Additional Paid-in Capital | 731.2 m | 734.7 m | 738 m | 772.3 m | 847.8 m | 847 m | 826.9 m | 831.8 m | 839.5 m |
Retained Earnings | (78.8 m) | (68.6 m) | (69.2 m) | (86.5 m) | (85.7 m) | (81.4 m) | |||
Total Equity | 712.2 m | 694.2 m | 668.9 m | 687.1 m | 770.8 m | 770.2 m | 735.3 m | 732.7 m | 747.9 m |
Financial Leverage | 1.1 x | 1.1 x | 1.2 x | 1.1 x | 1.1 x | 1.1 x | 1.7 x | 1.7 x | 1.7 x |
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Net Income | 176.2 m | 80.2 m | 125.3 m |
Depreciation and Amortization | 13.8 m | 25 m | 26.7 m |
Accounts Receivable | (1.9 m) | 2.5 m | (900 k) |
Inventories | (16 m) | (800 k) | (15 m) |
Accounts Payable | (1.5 m) | (3.1 m) | (3.1 m) |
Cash From Operating Activities | 190.2 m | 140.5 m | 166.3 m |
Capital Expenditures | (23.9 m) | (5 m) | |
Cash From Investing Activities | (17.7 m) | (91.4 m) | |
Cash From Financing Activities | (211.8 m) | (177.3 m) | (68.3 m) |
Income Taxes Paid | 108.2 m | ||
Free Cash Flow | 164.4 m | 161.3 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 89.3 k |
Financial Leverage | 1.7 x |
